ArticleAsian journal of neurosurgery2025
Utility of Immunohistochemistry in Subtyping Posterior Fossa Group A Ependymoma: A Retrospective Study.
Article in Asian journal of neurosurgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Posterior fossa ependymomas are classified into posterior fossa group A (PFA-EPN) and posterior fossa group B ependymomas. PFA-EPN shows immunohistochemical loss of H3 p.K27me3 expression. Molecular subgroup 1 (PFA-1) and 2 (PFA-2), encompass nine subtypes (PFA 1a-1f and 2a-2c). OTX2 and H3 p.K27M immunopositivity is noted in PFA-2c and 1f, respectively, with potential prognostic implications. Aim: To assess the frequency of OTX2 and H3 p.K27M immunopositivity in PFA-EPN. Materials and Methods: This retrospective study included PFA-EPN diagnosed at our institute from 2016 to 2022, based on immunohistochemical loss of expression of H3p.K27me3. Immunohistochemistry for OTX2 and H3 p.K27M was carried out on them. Results: A total of 42 cases of PFA-EPN were encountered, ranging 10 months to 23 years, with a median of 4 years. OTX2 immunopositivity was seen in four cases (9.5%) and H3 p.K27M positivity in two cases (4.8%). Follow-up data were available partially and showed variable survival. Conclusion: PFA-EPN can be segregated into OTX2 and H3 p.K27M immuno-positive tumors. Because of low frequency and few studies, long-term survival data are limited. Assessment of frequency of OTX2 and H3 p.K27M immunopositivity and their segregation into subsets with prognostic significance can help in diagnostics in routine laboratory settings. This can also potentiate open new therapeutic avenues in PFA-EPN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.